Renal Transplantation from Expanded Criteria Donors by Pooja Binnani et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Renal Transplantation from  
Expanded Criteria Donors 
Pooja Binnani, Madan Mohan Bahadur and Bhupendra Gandhi 
Jaslok Hospital and Research Centre, Mumbai 
India 
1. Introduction 
The 21st century has come as an era of chronic diseases including chronic kidney diseases. 
Treatment at the end stage of kidney failure involves replacing the lost functions of kidneys 
by dialysis or by a kidney transplant.  The end stage renal disease (ESRD) population is 
increasing worldwide. The National Kidney Foundation says that “rates of chronic kidney 
disease (CKD) in the United States have increased by more than 20% over the past decade, 
causing dramatic loss of life and sky-rocketing health care costs, according to the 2008 
annual report by the US Renal Data System”(National Kidney Foundation ,2009). 
Kidney transplantation was proven unquestionably the preferred therapy for most patients 
with ESRD. Survival, cardiovascular stability and quality of life were found superior in 
allograft recipients compared to similar patients who remained on dialysis (Wolfe et al, 
1999; Nathan et al, 2003).  
There was a large gap between the number of patients waiting for a transplant and the 
number receiving a transplant. This gap has widened over the decade, according to 2009 
OPTN/SRTR Annual report. The waiting list for a donor kidney has grown from slightly 
more than 40,000 people in 1998 to about 110,466 in 2011, as per UNOS (United Network for 
Organ Sharing) data base. Sometimes the wait is two or three years, but often it stretches to 
five or 10 years or longer. Some die while waiting. During the past few years, there has been 
renewed interest in the use of expanded criteria donors (ECD) for kidney transplantation to 
increase the numbers of deceased donor kidneys available. More kidney transplants would 
result in shorter waiting times and limit the morbidity and mortality associated with long-
term dialysis therapy.  
Performing renal transplant with a perfectly healthy kidney to all the patients with ESRD is 
an ideal scenario. But growing waiting lists and shortage of kidneys makes it necessary to 
make some compromises. Use of so-called, marginal or borderline donors can increase 
donor pool by almost 20 to 25%.  
Terms- expanded criteria donor or marginal donor simply means accepting suboptimal quality 
grafts, either from a living donor or a cadaver donor with some acceptable medical risks. 
Scientific Registry of Transplant Recipients (SRTR)/Organ Procurement and Transplantation 
Network (OPTN) data showed 41% discard rate for ECD kidneys. Common reasons for 
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discard of these donor kidneys were older donors, glomerulosclerosis on biopsy and poor 
renal perfusion (Sunga et al, 2008). Current utilization is 15% of all transplanted kidneys.  
2. Marginal versus expanded criteria donor 
Some authors believe that the term ‘expanded’ be used instead of “marginal” because the 
term ‘marginal’ may be considered pejorative by the patients who receive them, as well as 
by the programs that transplant them (Kauffman, 1997). 
3. Standard donor versus expanded criteria donors 
Graft and patient survival after ECD kidney transplantation are inferior to survival rates 
with SCD kidney transplantation. The differences are initially insignificant, but increase 
over time. The half-lives of deceased-donor kidneys (ECD or SCD) are shorter than the half-
life of a living-donor kidney (Metzger, 2003). Many large retrospective database analysis 
compared outcomes of standard-criteria donor (SCD) kidney transplants with ECD kidney 
transplants. Overall, mortality in the perioperative period was greater in ECD kidney 
recipients (Merion et al, 2005; Remuzzi et al, 2006). Kidneys transplanted from expanded 
criteria donors have a higher rate of delayed graft function, more acute rejection episodes, 
and decreased long-term graft function. Several factors, including prolonged cold ischemia 
time (CIT), increased immunogenicity, impaired ability to repair tissue, and impaired 
function with decreased nephron mass may contribute to this (De Fijter et al, 2001). Despite 
these inferior results, these transplants had definitely survival advantage over patients still 
receiving dialysis (Ojo et al, 2001; Merion et al, 2005).  It was also observed that, despite an 
increased mortality risk during the initial post-transplant period, the long-term mortality 
risk was > 50% lower for patients who were 60 to 74 years of age at the time of waiting list 
registration compared with those who remained on dialysis (Wolfe et al, 1999). 
4. Optimised allocation 
The strategy proposed by Bryce Kiberd et al was to retrieve all kidneys; but visibly scarred 
kidneys should be discarded. He also proposed performing biopsy in some deceased donors 
kidneys > age 65, > age 55 and donor Creatinine clearance<60 - 70 ml/min, discarding 
advanced arteriolar sclerosis or interstitial fibrosis. Allocating these grafts to Older (>59) or 
diabetic, avoid the sensitized, minimize cold ischemic time and avoid large weight or age 
mismatches (Bryce Kiberd, 2011). Schnitzler and colleagues used a Markov model to 
determine the best timing for an individual patient to accept an offer of an ECD kidney, 
based on registry data from the United States Renal Data System (USRDS) and expected 
quality-adjusted life years (Schnitzer et al, 2003). Common practice in the United States as 
well as Europe is to place older donor kidneys in older patients (Voiculescu et al, 2002; Smits 
et al, 2002; Kasiske et al, 2002; Lee et al, 1999).  
5. Types of marginal donors 
5.1 Living marginal donor 
Living‐related kidney donation is a way out of the current dilemma of insufficient supply of 
renal allografts. The risk to the donor is minimal, but not zero. Apart from these peri‐
operative risks, are there potential long‐term risks with respect to renal function, proteinuria  
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and hypertension. Potential risks must be excluded by careful work‐up of the donor (Duraj 
et al, 1995; Natarajan et al, 1992; Foster et al, 1991). There is enough evidence to suggest that, 
standard living donors do not face risks for ESRD any higher than those of age- matched 
peers (Fehrman‐Ekholm et al, 2001). But this doesn’t hold true for marginal living donors. In 
fact, emphasis should be given to ascertain the risk of developing CKD as well as ESRD in 
these donors.  
Marginal Donors - Inclusion 
 Elderly donors 
 GFR – 60 to 70 ml/ min 
 Mild Hypertension 
 Donor with Stone Disease 
 Donors with Renal cysts 
 Donors with BMI>30 
 Other issues like tuberculosis, DM, proteinuria, hematuria, malignancy, family history 
of ESRD and CMV Infections 
5.1.1 Aged kidney donors 
Glomerulosclerosis increases with age. There is decrease in GFR of approx 1 ml/min per 
1.73 m2 per year after age 40. There is a documented acute decrease in GFR of approximately 
30% after unilateral nephrectomy; however, the impact of unilateral nephrectomy on this 
rate of decline in GFR is unknown.  
Twenty per cent glomerulosclerosis is usually considered the upper limit for accepting 
kidneys from a donor. There is higher incidence of delayed graft function with such 
kidneys. Further, there may be associated increased rate of acute rejection. Advancing age is 
associated with higher incidence of hypertension (Moreso et al, 1999). The influence of 
donor age on the outcome of living donor kidney transplantation is not very clear. Gill et al 
in their observational cohort study of 23,754 kidney transplantations performed in recipients 
60 years and older, found that old living donor transplants were associated with inferior 3-
year graft survival rates, but similar 3-year patient survival rates compared with young 
living donor transplants. Elderly deceased criteria donor transplantations were associated 
with a greater risk of graft loss. He proposed old living donors an important option for 
elderly transplantation (Gill et al, 2008). There are other few studies in the literature that 
found encouraging results with elderly living donor transplants (Kumar et al, 2000; De La 
Vega, 2004). Graft survival, patient survival, degree of hypertension and renal function were 
similar in elderly and young living donor transplant groups.  Contrary to these encouraging 
results, others noted poor patient and graft survival in elderly donor transplants (Toma et al, 
2001; Prommool et al, 2000). Long term outcome of this group is not known.  
5.1.2 Hypertensive donors 
There are no precise guidelines regarding donation from patients with arterial hypertension. 
It is now accepted that systolic blood pressure greater than 140 mmHg is a much more 
www.intechopen.com
 
Renal Transplantation – Updates and Advances 20
important cardiovascular risk factor than raised diastolic blood pressure. In fact, there is 
little evidence that well-controlled hypertension may lead to kidney damage in an otherwise 
healthy subject. According to a Consensus Conference held in Amsterdam (Delmonico, 
2005), there is no reason to reject as a kidney donor a subject more than 50 years of age who 
has a normal blood pressure on therapy with a GFR > 80 ml/min and proteinuria < 300 mg 
per day(Delmonico et al, 2005). Ambulatory blood pressure monitoring has been proposed 
as a more sensitive method than office blood pressure measurements in identifying 
hypertension in living donors (Ozdemir et al, 2000).  
5.1.3 Diabetic donors 
Diabetics are generally excluded because of the increased risk of postoperative 
complications in the short term and because of the potential risk of developing diabetic 
nephropathy in the long term (Delmonico et al, 2005; Kasiske et al, 1995).  Diabetic 
nephropathy occurs in familial clusters and heredity helps to determine susceptibility to 
diabetic nephropathy (Sequist et al, 1989). It was clearly stated in Consensus Conference 
held in Amsterdam, that individuals with a history of diabetes or fasting blood glucose of ≥ 
126mg/dl (7.0mmol/L) on at least two occasions (or 2-h glucose with OGTT ≥ 200mg/dl 
(11.1mmol/L)) should not donate(Delmonico et al, 2005). 
5.1.4 Patients with nephrolithiasis 
It seems reasonable to accept as donors only those subjects without stones at the time of 
evaluation and with normal values within a 24-hour urine collection of calcium, urate, and 
oxalate. According to a Consensus Conference, patients with stones caused by inherited 
disorders, inflammatory bowel disease, or systemic disease are at high risk of recurrence 
and should not be considered for donation (Delmonico et al, 2005).  In the series a cohort of 
710 renal transplant recipients from mayo clinic, evaluation was done for the risk transplant 
graft renal calculus formation over duration of 4 years. 44 donor kidneys had calculi, 
majority being <2mm. Stable stone size was seen in four patients, increase in stone size 
averaging 2.9 millimeters in four patients. No loss of the transplanted kidneys occurred due 
to stone obstruction in the patients studied (Ho et al, 2005). Whether or not kidney stone 
formers should donate a kidney is controversial. The American Society of Transplantation 
(AST) position paper proposes guidelines that a kidney stone former may donate a kidney 
if: only one stone has ever formed; stones have been multiple, but none have formed for >10 
years and none are seen on radiograph; and the donor is screened for metabolic 
abnormalities and is offered life-long follow-up that includes periodic risk reassessment, 
medical treatment, and hydration (Michelle et al, 2006). 
5.1.5 Obese donors 
There is little information on the long-term follow-up of obese donors. Of some concern, in 
patients submitted to unilateral nephrectomy for various reasons, those with a BMI > 30 had 
a significantly higher risk of developing proteinuria or renal dysfunction in the long term 
than did those with a BMI < 30 (Praga et al, 2000). The Consensus Conference held in 
Amsterdam discouraged donation from persons with a BMI higher than 35(Delmonico et al, 
2005). Dyslipidemia are associated with decreased kidney function in the general population 
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and have faster rates of progression in patients who have chronic kidney disease. However, 
isolated dyslipidemia is not a contraindication for donation.  
5.1.6 Other issues 
 Adult relatives of patients with polycystic kidney disease can be accepted for donation 
if they have a normal CT or renal ultrasound scan. 
 Donors with malignancy- a history of malignancy is in general a contraindication to 
living kidney donation, other than carcinoma in situ of the uterine cervix or treated low 
grade, non- melanotic skin carcinoma.  
 Donors with transmissible infections- HIV positive status remains a contraindication for 
donation. Cytomegalovirus (CMV) and Ebstein-barr virus (EBV) status is measured at 
some transplant centers and they delay transplant till PCR for CMV becomes negative. 
Most of the adults are EBV and CMV-positive; most of the children are negative. The 
risk of post-transplantation lymphoproliferative disorder (PTLD) is the concern in CMV 
and EBV-negative individuals receiving positive donors. However, the risk is not as 
high to prohibit renal transplantation (Delmonico et al, 2005). Renal transplantation 
should be considered using HCV-seropositive grafts for qualified patients with chronic 
kidney disease (CKD) stage 5 and HCV infection since good information indicates that 
the transplantation of kidneys from HCV-infected donors results in improved survival 
compared to wait-listed and dialysis-dependent candidates (Fabrizi et al, 2009). 
Hepatitis C Virus (HCV) positive donor may be considered for donation to a HCV 
positive recipient only if the donor PCR is negative, certain genotypes (Genotype 4) are 
treated and eradicated of the donor and there is no evidence of chronic hepatitis or 
cirrhosis on liver biopsy. However, there is no data on live kidney transplantation from 
HCV positive donors. Hepatitis B Virus (HBV) positive status currently is not accepted 
for donation. However, there are some isolated reports of transplantation by groups in 
New Zealand (Delmonico et al, 2005). Donors treated for pulmonary TB require a more 
specific and extensive examination of the urinary tract and the kidneys prior to 
donation.  
5.1.7 Ethical issues 
Ethical issues in accepting marginal criteria donors are very complex. The living kidney 
donation means giving life to a patient on dialysis but at the same time avoiding risks to the 
donor. An important problem with marginal donors is that these marginal living donors 
may themselves add up the pool of chronic kidney disease patients in the long run.    
At American Transplant Congress 2003, in cases of marginal donor transplantation, a prior 
sample consent by both donor and recipient was proposed stating expect increase in 
delayed graft function, expected decrease in graft survival, expected decrease in waiting 
time, expected increase in survival compared to waiting and benefit of transplant prior to 
increased morbidity.  
It is truly anticipated that the transplantation of ECD and DCD kidneys would result in 
higher costs. More frequent need for hemodialysis, more hospital readmissions due to poor 
or late onset graft function and more opportunistic infections in recipients of ECD and DCD 
kidneys results in higher cost for their initial medical care. 
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5.2 Marginal cadaveric donor  
The Organ Procurement and Transplantation Network instituted a formalized definition of 
marginal kidneys in 2002 with the advent of the Expanded Criteria Donor (ECD) (Metzger et 
al, 2003).  These deceased donor kidneys were demonstrated to convey a 70% or greater risk 
for graft loss for transplant recipients relative to an ideal donation and were characterized 
by a donor age older than 60 yr or older than 50 yr and accompanied by two additional risk 
factors, including a history of hypertension, elevated terminal donor Creatinine, and 
cerebrovascular cause of death.  
Despite expected higher rate of graft failure compared to SCD kidneys, multiple studies 
have subsequently shown that kidney transplantation using ECDs is still associated with a 
substantial reduction in morbidity and improvement in life expectancy when compared 
with suitable transplant candidates who remained on maintenance dialysis treatment 
(UNOS Policy 3.5.1, 2002; Institute of Medicine, 1997; Ojo et al, 2001).  
6. Donation after cardiac death (DCD) 
Another approach to the organ shortage has been the utilization of donors after cardiac 
death. The recovery of organs from nonheart beating donors is an important, medically 
effective and ethically acceptable approach to reducing the gap that exists now and will 
continue to exist in future between the demand for and available supply of organs for 
transplantation’. A lot of investigators have reported excellent short-term outcomes using 
these donors, and 10–15% growth in organ donation as a result of the use of DCD donors 
was demonstrated. Multiple studies have shown that the overall results of DCD (without 
ECD characteristics) and SCD kidney transplants are comparable (Institute of Medicine, 
1997; Ojo et al, 2001; Stratta et al, 2004). A main issue with NHBD is the significantly higher 
rate of delayed graft function, compared with that associated with heart-beating donor 
(Keizer et al, 2005).  
7. Role of kidney biopsy 
Outcomes of ECD kidney transplantation are improved when a pre-implantation biopsy of 
the donor kidney is evaluated using the scoring system introduced by Karpinski and 
colleagues (Karpinski et al, 1999). Using this system, donor renal pathology is scored from 0 
to 3 (none to severe disease) in 4 areas: glomerulosclerosis, interstitial fibrosis, tubular 
atrophy, and vascular disease. A donor vessel score of 3/3 is associated with a 100% 
incidence of delayed graft function and a significantly worse renal function at one year. 
8. Patient management: Immunosuppressive protocols 
Optimal management is a challenge in ECD kidney transplant recipients. These transplants 
are feared with increased rates of acute rejections and delayed graft function. Therefore, 
adequate level of Immunosuppression is desired.  Management for an ECD kidney is based 
on potential nephron-protecting strategies, including cold ischemia time minimization, 
pulsatile perfusion preservation, immunosuppression focused on nephrotoxicity 
minimization, and adequate infection prophylaxis. Although calcineurin inhibitors are 
excellent drugs, the nephrotoxicity they impart is largely responsible for postponing chronic 
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allograft dysfunction and achieve better long-term graft survival. The problem of 
calcineurin inhibitor-related nephrotoxicity is an even greater concern in older recipients of 
ECD kidneys. Various strategies of CNI withdrawal, minimization as well as avoidance 
were utilized by a number of investigators.  
 Antibody induction, MMF, steroids. 
 MMF monotherapy or MMF plus steroids. 
 Antibody induction, sirolimus, MMF, steroids. 
 Antibody induction, sirolimus, MMF, steroids. 
 Conversion from a calcineurin-inhibitor-based regimen to a sirolimus-based regimen 
The potential for CNI-free sirolimus and MMF–based therapy in ECD kidney transplant 
recipients has not been adequately studied to date. Consequently, extrapolation of the best 
results obtained with anti–interleukin 2 receptors, MMF, steroids, and moderate exposure to 
tacrolimus might constitute an advisable strategy (Ekberg et al, 2007).  
9. Conclusion 
In summary, the use of marginal donors for kidney transplantation increases the numbers of 
donor kidneys available, results in shorter waiting times, and limits the morbidity and 
mortality associated with long-term dialysis therapy. These kidneys are known to have 
worse long-term survival than standard criteria kidneys. Elderly patients with longer 
waiting times show better survival receiving such kidney than remaining on dialysis 
therapy. A management protocol for ECD kidney transplantation should be based on 
potential nephronprotecting strategies like, minimization of cold ischemia time, tailored 
immunosuppression with early CNI minimization or delayed moderate dose, CNI addition 
after induction, and adequate infection prophylaxis.  
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